129 related articles for article (PubMed ID: 11843620)
1. Correlation of secondary structures of bradykinin B1 receptor antagonists with their activity.
Miskolzie M; Gera L; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2002 Feb; 19(4):585-93. PubMed ID: 11843620
[TBL] [Abstract][Full Text] [Related]
2. The importance of the N-terminal beta-turn in bradykinin antagonists.
Miskolzie M; Gera L; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2000 Oct; 18(2):249-60. PubMed ID: 11089646
[TBL] [Abstract][Full Text] [Related]
3. An NMR conformational analysis of cyclic bradykinin mimics. Evidence for a beta-turn.
Miskolzie M; Yamamoto H; York EJ; Stewart JM; Kotovych G
J Biomol Struct Dyn; 2000 Jun; 17(6):947-55. PubMed ID: 10949162
[TBL] [Abstract][Full Text] [Related]
4. A comparative NMR and molecular dynamics study of the conformations of bradykinin B1 and B2, B2, and B1-specific receptor antagonists B-9430, B-9436, and B-9858.
Sejbal J; Wang Y; Cann JR; Stewart JM; Gera L; Kotovych G
Biopolymers; 1997 Oct; 42(5):521-35. PubMed ID: 9322442
[TBL] [Abstract][Full Text] [Related]
5. A new class of pseudopeptide antagonists of the kinin B1 receptor containing alkyl spacers.
Galoppini C; Meini S; Tancredi M; Di Fenza A; Triolo A; Quartara L; Maggi CA; Formaggio F; Toniolo C; Mazzucco S; Papini A; Rovero P
J Med Chem; 1999 Feb; 42(3):409-14. PubMed ID: 9986712
[TBL] [Abstract][Full Text] [Related]
6. Backbone structure confirmation and side chain conformation refinement of a bradykinin mimic BKM-824 by comparing calculated (1)H, (13)C and (19)F chemical shifts with experiment.
Wang B; Miskolizie M; Kotovych G; Pulay P
J Biomol Struct Dyn; 2002 Aug; 20(1):71-80. PubMed ID: 12144353
[TBL] [Abstract][Full Text] [Related]
7. Bradykinin receptor antagonists containing N-substituted amino acids: in vitro and in vivo B(2) and B(1) receptor antagonist activity.
Goodfellow VS; Marathe MV; Kuhlman KG; Fitzpatrick TD; Cuadrado D; Hanson W; Zuzack JS; Ross SE; Wieczorek M; Burkard M; Whalley ET
J Med Chem; 1996 Mar; 39(7):1472-84. PubMed ID: 8691478
[TBL] [Abstract][Full Text] [Related]
8. Structural modification of the highly potent peptide bradykinin B1 receptor antagonist B9958.
Gera L; Stewart JM; Fortin JP; Morissette G; Marceau F
Int Immunopharmacol; 2008 Feb; 8(2):289-92. PubMed ID: 18182242
[TBL] [Abstract][Full Text] [Related]
9. N-terminal extended conjugates of the agonists and antagonists of both bradykinin receptor subtypes: structure-activity relationship, cell imaging using ligands conjugated with fluorophores and prospect for functionally active cargoes.
Gera L; Roy C; Bawolak MT; Charest-Morin X; Marceau F
Peptides; 2012 Apr; 34(2):433-46. PubMed ID: 22349904
[TBL] [Abstract][Full Text] [Related]
10. An NMR, CD, molecular dynamics, and fluorometric study of the conformation of the bradykinin antagonist B-9340 in water and in aqueous micellar solutions.
Sejbal J; Cann JR; Stewart JM; Gera L; Kotovych G
J Med Chem; 1996 Mar; 39(6):1281-92. PubMed ID: 8632435
[TBL] [Abstract][Full Text] [Related]
11. Structural characterization of lipopeptide agonists for the bradykinin B2 receptor.
Giragossian C; Nardi E; Savery C; Pellegrini M; Meini S; Maggi CA; Papini AM; Mierke DF
Biopolymers; 2001 Apr; 58(5):511-20. PubMed ID: 11241222
[TBL] [Abstract][Full Text] [Related]
12. B-9972 (D-Arg-[Hyp3,Igl5,Oic7,Igl8]-bradykinin) is an inactivation-resistant agonist of the bradykinin B2 receptor derived from the peptide antagonist B-9430 (D-Arg-[Hyp3,Igl5,D-Igl7,Oic8]-bradykinin): pharmacologic profile and effective induction of receptor degradation.
Bawolak MT; Gera L; Morissette G; Stewart JM; Marceau F
J Pharmacol Exp Ther; 2007 Nov; 323(2):534-46. PubMed ID: 17699739
[TBL] [Abstract][Full Text] [Related]
13. Potent, long-acting bradykinin antagonists for a wide range of applications.
Stewart JM; Gera L; Chan DC; Whalley ET; Hanson WL; Zuzack JS
Can J Physiol Pharmacol; 1997 Jun; 75(6):719-24. PubMed ID: 9276154
[TBL] [Abstract][Full Text] [Related]
14. Combination cancer chemotherapy with one compound: pluripotent bradykinin antagonists.
Stewart JM; Gera L; Chan DC; York EJ; Simkeviciene V; Bunn PA; Taraseviciene-Stewart L
Peptides; 2005 Aug; 26(8):1288-91. PubMed ID: 15878795
[TBL] [Abstract][Full Text] [Related]
15. Agonist activity at the kinin B1 receptor: structural requirements of the central tetrapeptide.
Rovero P; Pellegrini M; Di Fenza A; Meini S; Quartara L; Maggi CA; Formaggio F; Toniolo C; Mierke DF
J Med Chem; 2001 Jan; 44(2):274-8. PubMed ID: 11170638
[TBL] [Abstract][Full Text] [Related]
16. MEN 11270, A novel selective constrained peptide antagonist with high affinity at the human B2 kinin receptor.
Meini S; Quartara L; Rizzi A; Patacchini R; Cucchi P; Giolitti A; Calò G; Regoli D; Criscuoli M; Maggi CA
J Pharmacol Exp Ther; 1999 Jun; 289(3):1250-6. PubMed ID: 10336513
[TBL] [Abstract][Full Text] [Related]
17. Inflammation modifies the role of cyclooxygenases in the contractile responses of the rat detrusor smooth muscle to kinin agonists.
Meini S; Lecci A; Cucchi P; Catalioto RM; Criscuoli M; Maggi CA
J Pharmacol Exp Ther; 1998 Oct; 287(1):137-43. PubMed ID: 9765332
[TBL] [Abstract][Full Text] [Related]
18. Probing the topological arrangement of the N- and C-terminal residues of bradykinin for agonist activity at the B1 receptor.
Pellegrini M; Tancredi M; Rovero P; Mierke DF
J Med Chem; 1999 Aug; 42(17):3369-77. PubMed ID: 10464023
[TBL] [Abstract][Full Text] [Related]
19. A fluorescent version of the bradykinin B2 receptor antagonist B-9430: pharmacological characterization and use in live cell imaging.
Bawolak MT; Gera L; Bouthillier J; Stewart JM; Adam A; Marceau F
Peptides; 2008 Sep; 29(9):1626-30. PubMed ID: 18565624
[TBL] [Abstract][Full Text] [Related]
20. Proton magnetic resonance studies of bradykinin antagonists.
Liu X; Stewart JM; Gera L; Kotovych G
Biopolymers; 1993 Aug; 33(8):1237-47. PubMed ID: 8364157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
